Neuroleptic Malignant Syndrome Associated With Clozapine Monotherapy
- 10 September 1993
- journal article
- case report
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 13 (5) , 510-514
- https://doi.org/10.1002/j.1875-9114.1993.tb04317.x
Abstract
Neuroleptic malignant syndrome is thought to be a result of dopamine receptor blockade in the striatum. Clozapine has only weak affinity for dopamine type 1 and 2 receptors, and therefore it was thought this drug would not precipitate the syndrome. However, six cases of the syndrome have been reported in patients receiving clozapine monotherapy. A review of the pathoetiology of symptoms occurring in the syndrome is included.This publication has 7 references indexed in Scilit:
- Multiple dopamine D4 receptor variants in the human populationNature, 1992
- An Apparent Neuroleptic Malignant Syndrome Without Extrapyramidal Symptoms Upon Initiation of Clozapine TherapyJournal of Clinical Psychopharmacology, 1992
- Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapineNature, 1991
- Atypical Neuroleptic Malignant Syndrome (NMS) with an Atypical Neuroleptic Clozapine-induced NMS without RigidityAnnals of Clinical Psychiatry, 1990
- The (Frequently) Neuroleptic (Potentially) Malignant SyndromeThe British Journal of Psychiatry, 1990
- Neuroleptic malignant syndrome: review and analysis of 115 casesBiological Psychiatry, 1987
- Neuroleptic Malignant SyndromeSouthern Medical Journal, 1986